Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 11/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347572 | 0.80 | ALDH1A1 (0.46) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3092003 | 0.79 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL18456933 | 0.79 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL12355447 | 0.79 | CHRNA7 (0.46) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL12355547 | 0.75 | PTGDR2 (0.64) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL15428822 | 0.75 | PTGDR2 (0.61) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL15428826 | 0.72 | PTGDR2 (0.65) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL3663654 | 0.72 | PTGDR2 (0.65) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL28840719 | 0.71 | TERT (0.47) | PTGDR2PTGDR | |
| SCHEMBL15428823 | 0.70 | PTGDR2 (0.63) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017005764-A1 | A PROCESS TO MAKE TRICYCLOKETONE INTERMEDIATES OF CRTH2 ANTAGONISTS | INTERVET INTERNATIONAL B.V. (NL) | 2017-01-12 | — | — | WO | disclosed |
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |